{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:53:57Z","timestamp":1773971637860,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23159-9","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:33:28Z","timestamp":1762886008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Added prognostic value of baseline pre-infusion 18F-FDG PET\/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2271-9764","authenticated-orcid":false,"given":"Seyed Ali","family":"Mirshahvalad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Kohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshini","family":"Kulanthaivelu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ur","family":"Metser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kridel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sita","family":"Bhella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Veit-Haibach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"23159_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras, L. R. et al. 2016 US lymphoid malignancy statistics by world health organization subtypes. Cancer J. Clin. 66, 443\u2013459 (2016).","journal-title":"Cancer J. Clin."},{"key":"23159_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya, S. & Barta, S. K. Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management.. Am. J. Hematol. 96, 617\u2013629 (2021).","journal-title":"Am. J. Hematol."},{"key":"23159_CR3","doi-asserted-by":"publisher","first-page":"103377","DOI":"10.1016\/j.critrevonc.2021.103377","volume":"163","author":"C Visco","year":"2021","unstructured":"Visco, C. et al. Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis. Crit. Rev. Oncol. Hematol. 163, 103377 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"23159_CR4","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00259-021-05551-5","volume":"49","author":"D Cohen","year":"2022","unstructured":"Cohen, D. et al. [(18)F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. Eur. J. Nucl. Med. Mol. Imaging. 49, 953\u2013962. https:\/\/doi.org\/10.1007\/s00259-021-05551-5 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"23159_CR5","doi-asserted-by":"publisher","first-page":"20210470","DOI":"10.1259\/bjr.20210470","volume":"94","author":"SA Milgrom","year":"2021","unstructured":"Milgrom, S. A., Rechner, L. & Berthelsen, A. The optimal use of PET\/CT in the management of lymphoma patients. Br. J. Radiol. 94, 20210470. https:\/\/doi.org\/10.1259\/bjr.20210470 (2021).","journal-title":"Br. J. Radiol."},{"issue":"2","key":"23159_CR6","first-page":"e2330301","volume":"222","author":"V Murad","year":"2023","unstructured":"Murad, V., Kohan, A., Ortega, C., Prica, A. & Veit-Haibach, P. Role of FDG PET\/CT in Patients With Lymphoma Treated With CAR T-Cell Therapy: Current Concepts. American J. Roentgenology 222(2), e2330301 (2023).","journal-title":"American J. Roentgenology"},{"key":"23159_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04587-4","author":"TW Georgi","year":"2023","unstructured":"Georgi, T. W. et al. Prognostic value of baseline and early response FDG-PET\/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy. J. Cancer Res. Clin. Oncol. https:\/\/doi.org\/10.1007\/s00432-023-04587-4 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"23159_CR8","doi-asserted-by":"publisher","first-page":"713577","DOI":"10.3389\/fonc.2021.713577","volume":"11","author":"R Hong","year":"2021","unstructured":"Hong, R. et al. Tumor burden measured by 18F-FDG PET\/CT in predicting efficacy and adverse effects of chimeric antigen receptor T-Cell therapy in Non-Hodgkin lymphoma. Front. Oncol. 11, 713577. https:\/\/doi.org\/10.3389\/fonc.2021.713577 (2021).","journal-title":"Front. Oncol."},{"key":"23159_CR9","doi-asserted-by":"publisher","first-page":"664688","DOI":"10.3389\/fonc.2021.664688","volume":"11","author":"L Vercellino","year":"2021","unstructured":"Vercellino, L. et al. Current and future role of medical imaging in guiding the management of patients with relapsed and refractory Non-Hodgkin lymphoma treated with CAR T-Cell therapy. Front. Oncol. 11, 664688. https:\/\/doi.org\/10.3389\/fonc.2021.664688 (2021).","journal-title":"Front. Oncol."},{"key":"23159_CR10","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1200\/JCO.21.02063","volume":"40","author":"NG Mikhaeel","year":"2022","unstructured":"Mikhaeel, N. G. et al. Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: international metabolic prognostic index. J. Clin. Oncol. 40, 2352 (2022).","journal-title":"J. Clin. Oncol."},{"key":"23159_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/RLU.0000000000003756","volume":"46","author":"P Sesques","year":"2021","unstructured":"Sesques, P. et al. Prognostic impact of 18F-FDG PET\/CT in patients with aggressive B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T cells. Clin. Nucl. Med. 46, 627\u2013634 (2021).","journal-title":"Clin. Nucl. Med."},{"key":"23159_CR12","doi-asserted-by":"crossref","unstructured":"Nioche, C. et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 78(16), 4786\u20136789 (2018).","DOI":"10.1158\/0008-5472.CAN-18-0125"},{"key":"23159_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","volume":"32","author":"AS Cottereau","year":"2021","unstructured":"Cottereau, A. S. et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT. Ann. Oncol. 32, 404\u2013411 (2021).","journal-title":"Ann. Oncol."},{"key":"23159_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2967\/jnumed.123.266322","volume":"65","author":"KB Girum","year":"2024","unstructured":"Girum, K. B. et al. Tumor location relative to the spleen is a prognostic factor in lymphoma patients: a demonstration from the REMARC trial. J. Nucl. Med. 65, 313\u2013319 (2024).","journal-title":"J. Nucl. Med."},{"key":"23159_CR15","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel, N. G. et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur. J. Nucl. Med. Mol. Imaging. 43, 1209\u20131219 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"23159_CR16","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","volume":"22","author":"AS Cottereau","year":"2016","unstructured":"Cottereau, A. S. et al. Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma. Clin. Cancer Res. 22, 3801\u20133809 (2016).","journal-title":"Clin. Cancer Res."},{"key":"23159_CR17","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1182\/blood.V130.Suppl_1.824.824","volume":"130","author":"L Kostakoglu","year":"2017","unstructured":"Kostakoglu, L. et al. Baseline PET-derived metabolic tumor volume metrics predict progression-free and overall survival in DLBCL after first-line treatment: results from the phase 3 GOYA study. Blood 130, 824 (2017).","journal-title":"Blood"},{"key":"23159_CR18","first-page":"1396","volume":"135","author":"L Vercellino","year":"2020","unstructured":"Vercellino, L. et al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood J. Am. Soc. Hematol. 135, 1396\u20131405 (2020).","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"23159_CR19","doi-asserted-by":"publisher","first-page":"664688","DOI":"10.3389\/fonc.2021.664688","volume":"11","author":"L Vercellino","year":"2021","unstructured":"Vercellino, L. et al. Current and future role of medical imaging in guiding the management of patients with relapsed and refractory non-hodgkin lymphoma treated with CAR T-Cell therapy. Front. Oncol. 11, 664688 (2021).","journal-title":"Front. Oncol."},{"key":"23159_CR20","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean, E. A. et al. High metabolic tumor volume is associated with decreased efficacy of Axicabtagene Ciloleucel in large B-cell lymphoma. Blood Adv. 4, 3268\u20133276 (2020).","journal-title":"Blood Adv."},{"key":"23159_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00259-023-06427-6","volume":"51","author":"E Marchal","year":"2024","unstructured":"Marchal, E. et al. Baseline [18F] FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphoma. Eur. J. Nucl. Med. Mol. Imaging. 51, 481\u2013489 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"23159_CR22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.269670","author":"A Farolfi","year":"2025","unstructured":"Farolfi, A. et al. Semiquantitative PET parameters refine prognosis in CAR T\u2013treated lymphoma after 1 and 3 months: a prospective single-center study. J. Nucl. Med. https:\/\/doi.org\/10.2967\/jnumed.125.269670 (2025).","journal-title":"J. Nucl. Med."},{"key":"23159_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.119.229450","volume":"61","author":"AS Cottereau","year":"2020","unstructured":"Cottereau, A. S. et al. 18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J. Nucl. Med. 61, 40\u201345 (2020).","journal-title":"J. Nucl. Med."},{"key":"23159_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12880-023-01138-8","volume":"23","author":"J Dang","year":"2023","unstructured":"Dang, J. et al. Predictive value of Dmax and% \u2206SUVmax of 18F-FDG PET\/CT for the prognosis of patients with diffuse large B-cell lymphoma. BMC Med. Imaging. 23, 173 (2023).","journal-title":"BMC Med. Imaging"}],"updated-by":[{"DOI":"10.1038\/s41598-026-36849-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23159-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23159-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23159-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T09:46:48Z","timestamp":1769593608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23159-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23159"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23159-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-36849-9","URL":"https:\/\/doi.org\/10.1038\/s41598-026-36849-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present study received institutional review board and ethics committee approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Due to the retrospective nature of the study, obtaining written informed consent was waived by the ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"39540"}}